The Discovery of Growth Hormone‐Releasing Hormone1: An Update

  title={The Discovery of Growth Hormone‐Releasing Hormone1: An Update},
  author={Michael O Thorner},
  journal={Journal of Neuroendocrinology},
  • M. Thorner
  • Published 1 June 2008
  • Biology, Medicine
  • Journal of Neuroendocrinology
The discovery of growth hormone-releasing hormone (GHRH) held the promise of the development of a new approach to restore the somatotrophic axis in patients with hypothalamic pituitary disease and also in other individuals in whom growth hormone is reduced, such as elderly people. Exogenous growth hormone (GH) has been used, but it is associated with a number of adverse effects, particularly when given at high doses. Exogenous GH does not reproduce the normal pulsatile pattern of GH observed in… 


Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects.
Polyethylene glycol-conjugated PEG-GHRH offers the possibility of less frequent dosing compared with GHRH, and deserves further clinical testing.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility, and the marked enhancement of trough GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF- I.
Acceleration of growth in two children treated with human growth hormone-releasing factor.
Growth hormone--releasing factor can restore growth hormone secretion and its biologic effects, including an increase in nitrogen retention, an increaseIn serum somatomedin C, and acceleration of linear growth in children with growth hormone deficiency.
Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.
GH pulses are a result of GRF secretion that is associated with a diminution or withdrawal of somatostatin secretion and there was augmentation of naturally occurring GH pulses, which is in contrast to the effect of gonadotropin-releasing hormone on gonadotropic hormone.
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.
GHRH administered as a once daily dose of 30 micrograms/kg GHRH.(1-29), s.c., was effective in increasing height velocity in GH-deficient children.
Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor.
Elevated serum GH and somatomedin C levels in a patient with an enlarged sella turcica and the characteristic responses seen in acromegaly to TRH, dopamine, and glucose do not occur exclusively in patients with discrete pituitary tumors and acromegalic, so consideration of ectopic GRF secretion should be made.
Effect of frequency of growth hormone administration on longitudinal bone growth and body weight in hypophysectomized rats.
The results of the present study demonstrate that the frequency of GH administration influence body growth and suggest that the secretory pattern of GH influence the growth rate under in vivo condition.
Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma.
Evaluation of plasma stability of potential GRH super analogues, designed to resist degradation by these enzymes, confirmed that GRH degradation in plasma occurs primarily by DPP IV, and to a lesser extent by trypsin-like enzyme(s).
Effects of TH9507, a growth hormone releasing factor (GRF) analog on HIV-associated abdominal fat accumulation: a multicenter, double-blind, randomization trial
  • Proc 89th Meeting of the Endocrine Soc OR41-4
  • 2007